

- 1 Ultrasound evaluation of vagus nerve cross-sectional area in a community-dwelling elderly
- 2 Japanese cohort
- 3
- 4 Kazumasa Oura*, Hiroshi Akasaka, Naoki Ishizuka, Yuriko Sato, Masahiro Kudo, Takashi
- 5 Yamaguchi, Mao Yamaguchi Oura, Ryo Itabashi, and Tetsuya Maeda
- 6
- 7 Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine,
- 8 Iwate Medical University, 2-1-1 Idaidori, Yahaba-Cho, Shiwa-Gun, Iwate 028-3695, Japan
- 9
- 10 *Corresponding author
- 11 E-mail: koura@iwate-med.ac.jp (KO)
- 12

13 Author Contributions

- 14 Conceptualization: K.O., T.M. Data curation: H.A, N.I. Formal analysis, H.A. Funding
15 acquisition, T.M. Investigation, H.A., N.I., Y.S., M.K., T.Y., M.Y.O. Methodology, K.O., H.A.
16 Project administration: K.O., H.A., T.M. Resources: H.A., N.I., T.M. Software: H.A.
17 Supervision: R.I., T.M. Validation, M.Y.O., R.I. Writing of the original draft: K.O. Writing,
18 review, and editing: M.O., R.I., T.M.
19

20 Abstract

21 **Objectives:** Although the vagus nerve (VN) is easily observed by ultrasonography, few studies
22 have evaluated the cross-sectional area (CSA) of the VN in healthy older individuals from East
23 Asia. In this study, we aimed to report reference values for the CSA of the VN in community-
24 dwelling elderly Japanese individuals and to identify any associated medical history and/or
25 lifestyle factors.

26 **Methods:** The present study included 336 participants aged ≥ 65 years from a prospective
27 cohort study conducted in Yahaba, Japan from October 2021 to February 2022. The CSA of the
28 VN was measured bilaterally at the level of the thyroid gland by ultrasonography. Univariate
29 and multivariable linear regression analyses were conducted to identify the associations between
30 clinical and background factors and the CSA of the VN on each side.

31 **Results:** In our cohort, the median CSA of the VN was 1.3 mm² (interquartile range [IQR] 1.1–
32 1.6) on the right side and 1.2 mm² (IQR 1.0–1.4) on the left side. Multivariable linear regression
33 analysis showed that history of head injury ($\beta = -0.15$, $p < .01$), history of convulsion ($\beta = 0.19$,
34 $p < .01$), and BMI ($\beta = 0.30$, $p < .01$) were independently associated with the CSA of the VN on
35 the left side. In contrast, there were no independent associations between any of the assessed
36 variables and the CSA on the right side.

37 **Conclusion:** We have reported reference VN CSA values for community-dwelling elderly
38 Japanese individuals. In addition, we showed that the CSA of the VN on the left side was
39 positively associated with a history of convulsive seizure and BMI and inversely associated with
40 a history of head injury.

41 **Keywords:** vagus nerve, nerve cross-sectional area, neuromuscular ultrasound, reference values,
42 elderly

43

44 Introduction

45 The utility of ultrasonography for imaging the vagus nerve (VN) was first reported in 1998 [1].
46 Since then, ultrasonography has been used to assess the cross-sectional area (CSA) of the VN in
47 patients with a variety of neurological conditions in order to investigate potential pathological
48 changes. Such conditions include neurodegenerative diseases such as Parkinson's Disease [2–7]
49 and amyotrophic lateral sclerosis [8–10], neuropathies such as Charcot-Marie-Tooth [11, 12],
50 Guillain-Barré syndrome [13], and transthyretin familial amyloid polyneuropathy [14], as well
51 as fibromyalgia [15]. Significant reductions in the CSA of the VN have been observed on the
52 right side [5] or on both sides in Parkinson's disease [3, 4, 6] and on both sides in ALS [9, 10],
53 correlating variably with disease severity and duration and age [3, 4, 9, 10]. However, not all
54 studies have identified differences [2, 7, 8]. In addition, Liu et al. [13] showed enlargement of
55 the VN on both sides in a cohort of northern Chinese patients with Guillain-Barré syndrome
56 subtypes; the VN was larger in patients exhibiting autonomic dysfunction. Furthermore,
57 recently, we have shown the cross-sectional area (CSA) of the VN on the right side to be an
58 independent predictor of atrial fibrillation (AF) in a cohort of Japanese patients following acute
59 ischemic stroke or transient ischemic attack [16].

60

61 As ultrasound of the peripheral nerves is being increasingly used to conduct structural
62 assessments in various diseases, well-defined reference values for the CSA of the VN are
63 essential. Recently, a meta-analysis of CSA reference values for the VN in healthy adults was
64 published [17]. In addition, some studies have shown the VN CSA to be relatively small in
65 Chinese patient cohorts; however, these studies were small-scale [14] or did not distinguish
66 between left and right VN [13, 14] and were not conducted in particularly aged populations.
67 Thus, overall, data regarding the VN in older East Asian—and specifically Japanese—
68 populations are lacking. This study aimed to determine reference values for the CSA of the VN
69 in community-dwelling elderly Japanese individuals and to identify any medical history and/or
70 lifestyle factors associated with these values.

71

72 Materials and Methods

73 Study population

74 The Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) is a
75 multicenter prospective cohort study of dementia that surveyed more than 10,000 community-
76 dwelling elderly persons aged 65 years or older at eight study sites in Japan [18]. Among the
77 participants in the JPSC-AD, only those who enrolled in the Yahaba Active Aging and Healthy
78 Brain (YAHABA) study for the residents of Yahaba Town (Iwate Prefecture, Japan) were

79 included in the present study. The YAHABA study is a community-based prospective cohort
80 study that was established in 2016 to clarify the risk factors and etiology of dementia,
81 cerebrovascular diseases, and movement disorders in older adults [19]. The study protocol
82 complied with the ethical guidelines of the 2013 Declaration of Helsinki. The Iwate Medical
83 University School of Medicine Institutional Ethics Committee reviewed and approved the
84 protocol (no. HG2020-017), and written informed consent was obtained from all participants.
85
86 This cross-sectional study of the VN was conducted from October 2021 to February 2022. All
87 participants underwent ultrasonography to evaluate the CSA of the VN. At the time of
88 examination, the following data were collected: history of stroke, cardiovascular disease,
89 congestive heart failure, AF, malignancy, respiratory disease, liver disease, convulsion,
90 depression, head or non-head traumatic injury (i.e., fractures or injuries requiring
91 hospitalization), Parkinson's disease, and other neurological diseases (including dementia); the
92 incidence of autonomic disorders in the subjects was not recorded. Moreover, clinical
93 backgrounds including the prevalence of hypertension, dyslipidemia, diabetes mellitus (DM),
94 and smoking and drinking habits were collected from all participants. Cardiovascular disease
95 was defined as coronary heart disease or coronary intervention. Participants' medical records
96 and documents used for regular health checks in the YAHABA study were obtained and their

97 medical history and biomarkers were compiled. All information on medical history was based
98 on the self-reports of the study participants. Convulsion was defined as the previous occurrence
99 of at least one convulsive seizure, with or without a diagnosis of epilepsy. Height, weight, body
100 mass index (BMI), and blood pressure were measured. Blood pressure was measured three
101 times using an automated sphygmomanometer with the study participants in a seated position
102 after at least 5 minutes of rest; the average of the three measurements was calculated [18].
103 Height and weight were measured while the participants were wearing light clothing without
104 shoes, and BMI was calculated. Casual blood samples were drawn from the antecubital vein of
105 all participants to test the fasting blood glucose and hemoglobin A1c concentrations.
106 Participants with a fasting blood glucose concentration ≥ 126 mg/dL (7.0 mmol/L) or
107 hemoglobin A1c concentration $\geq 6.5\%$ or who reported a history of DM were considered to
108 have DM. Although the YAHABA study examined other parameters such as liver and kidney
109 function and lipid concentrations [19], only fasting blood glucose and hemoglobin A1c
110 concentrations were analyzed in the present study.

111 **Ultrasound imaging**

112 Ultrasound to evaluate the CSA of the VN was performed using an EPIQ CVx (Philips Japan,
113 Tokyo, Japan), Aplio 400 (Canon Medical Systems, Otawara, Japan), Logiq S8 (GE Healthcare
114 Japan, Tokyo, Japan), or Voluson E8 (GE Healthcare Japan, Tokyo, Japan). Linear probes (7–

115 12 MHz) were used in all examinations. Ultrasonography and measurements of the CSA of the
116 VN were performed by one of the five medical laboratory technicians who specialized in
117 ultrasound examination and were blinded to each patient's clinical information; imaging was
118 conducted once per patient. Cross-sectional imaging of the VN was recorded bilaterally at the
119 level of the thyroid gland [2]. Measurements taken at this level have the advantages of easy
120 identification and good inter-rater agreement [20], while analysis at a single position was used
121 to minimize testing time and patient burden. Based on the Digital Imaging and Communications
122 in Medicine files stored in the ultrasound equipment, the CSA (reported in mm² by the
123 ultrasound system) of the VN was measured after manual tracing of the periphery of the VN
124 section.

125

126 **Statistical analysis**

127 The values were expressed as median and interquartile range (IQR), mean and standard
128 deviation, or number and frequency, as appropriate. Simple linear regression analysis was used
129 to evaluate the associations between the CSA of the VN and the individual background
130 characteristics of the participants. Factors that were significant in the simple linear regression
131 analysis were selected for evaluation as independent parameters by multivariate analysis. For
132 the multivariable linear regression analysis, the World Health Organization BMI classification

133 was used to categorize the participants as underweight (BMI < 18.5 kg/m²), normal (BMI 18.5–
134 24.9 kg/m²), overweight (BMI 25.0–29.9 kg/m²), or obese (BMI ≥ 30 kg/m²) [21]. All statistical
135 analyses were conducted using SPSS version 26 (IBM Japan, Tokyo, Japan), and $p < 0.05$ was
136 considered statistically significant.

137

138 Results

139 After excluding 10 subjects who were incapable of providing informed consent, a total of 336
140 participants were included in this study. The characteristics of the participants are shown in
141 Table 1. Ultrasound imaging (Fig.1) showed that in our study population, the median CSA of
142 the VN was significantly smaller on the left side than on the right side (1.2 mm² versus 1.3
143 mm², $p < .01$), in line with previous studies [17, 20, 22, 23].

144

145 Table 1. Characteristics of the study participants

Variables	
Age (years), median [IQR]	75.5 [73–80]
Male sex, no. (%)	150 (44.6)
Stroke, no. (%)	24 (7.1)

Cardiovascular disease, no. (%)	20 (6.0)
Atrial fibrillation, no. (%)	24 (7.1)
Congestive heart failure, no. (%)	7 (2.1)
Malignancy, no. (%)	51 (15.2)
Respiratory disease, no. (%)	51 (15.2)
Liver disease, no. (%)	43 (12.8)
Head injury, no. (%)	27 (8.0)
Non-head injury, no. (%)	124 (36.9)
Depression, no. (%)	4 (1.2)
Convulsion, no. (%)	3 (0.9)
Parkinson's disease, no. (%)	0 (0)
Other neurological disease, no. (%)	30 (8.9)
Hypertension, no. (%)	218 (64.9)
Dyslipidemia, no. (%)	136 (40.5)
Diabetes mellitus, no. (%)	59 (17.6)
Current smoker, no. (%)	108 (32.1)
Regular alcohol consumption, no. (%)	128 (38.1)
Height (cm), median [IQR]	154 [148–162]

Weight (kg), median [IQR]	57 [49–66]
BMI (kg/m ²), median [IQR]	23.8 [21.6–26.2]
BMI category, no. (%)	
<18.5 kg/m ²	14 (4.2)
18.5–24.9 kg/m ²	199 (59.6)
25.0–29.9 kg/m ²	102 (30.5)
≥ 30 kg/m ²	19 (5.7)
Fasting blood glucose (mmol/L), median [IQR]	6.53 [5.60–7.90]
Hemoglobin A1c (NGSP %), median [IQR]	5.6 [5.4–5.9]
Systolic blood pressure (mmHg), median [IQR]	143.7 [131.1–159.3]
Diastolic blood pressure (mmHg), median [IQR]	75.0 [68.0–82.3]
Right VN CSA (mm ²), median [IQR]	1.3 [1.1–1.6]
Left VN CSA (mm ²), median [IQR]	1.2 [1.0–1.4]

146 VN, vagus nerve; CSA, cross-sectional area; IQR, interquartile range; no., number; BMI, body

147 mass index; NGSP, National Glycohemoglobin Standardization Program.

148

149 Fig. 1 Ultrasonographic image of the vagus nerve.

150 The vagus nerve is shown as a small, rounded, hypoechoic structure between the carotid artery
151 and jugular vein. The cross-sectional area of the vagus nerve was measured by manual tracing
152 (yellow circle). A, common carotid artery; V, jugular vein.

153

154 We conducted simple linear regression analysis to determine the relationship between the
155 background of the participants and the CSA of the VN on the left and right sides (Table 2). Sex,
156 height, body weight, BMI, and smoking habit were significantly associated with the CSA of the
157 right VN. Furthermore, body weight, BMI, head injury, convulsion, hypertension, and smoking
158 habit were significantly associated with the CSA of the left VN.

159

160 **Table 2. Simple linear regression analysis of the association between vagus nerve cross-**
161 **sectional area and background of the participants.**

	Cross-sectional area of the vagus nerve			
	Right		Left	
	R ²	<i>p</i> -value	R ²	<i>p</i> -value
Sex	0.022	< .01	0.006	.15
Age	0.001	.55	0.001	.67
Height	0.036	< .01	0.007	.12

Body weight	0.040	< .01	0.064	< .01
Body mass index	0.015	.03	0.067	< .01
Stroke	< 0.001	.84	< 0.001	.95
Cardiovascular disease	0.004	.26	< 0.001	.73
Atrial fibrillation	0.001	.50	< 0.001	.94
Congestive heart failure	< 0.001	.78	< 0.001	.99
Malignancy	< 0.001	.84	< 0.001	.69
Respiratory disease	< 0.001	.87	0.001	.54
Liver disease	0.003	.35	0.001	.54
Head injury	0.005	.21	0.014	.03
Non-head injury	< 0.001	.82	0.002	.43
Depression	< 0.001	.92	0.002	.37
Convulsion	0.002	.42	0.025	< .01
Other neurological disease	0.002	.40	< 0.001	.97
Hypertension	0.002	.41	0.012	.04
Dyslipidemia	0.002	.43	< 0.001	.94
Diabetes mellitus	< 0.001	.98	0.001	.53
Fasting blood glucose	0.005	.21	< 0.001	.72

Hemoglobin A1c	0.001	.60	0.001	.61
Current smoker	0.013	.03	0.013	.04
Regular alcohol consumption	0.008	.11	.003	.30
Systolic blood pressure	< 0.001	.74	0.005	.18
Diastolic blood pressure	0.001	.52	0.005	.21

162

163 Multivariable linear regression analysis with adjustments for age, sex, BMI, AF, DM, head
 164 injury, convulsion, hypertension, and smoking habit showed that history of head injury ($\beta = -$
 165 $0.15, p < .01$), history of convulsion ($\beta = .19, p < .01$), and BMI ($\beta = .30, p < .01$) were
 166 independently associated with the CSA of the VN on the left side, while none of the variables
 167 were significantly associated with the CSA of the VN on the right side (Table 3).

168

169 **Table 3. Multivariable linear regression analysis of variables associated with vagus nerve**

170 **cross-sectional area**

	Right cross-sectional area		Left cross-sectional area	
	β	<i>p</i> -value	β	<i>p</i> -value
Male sex	-0.13	.10	0.05	.50
Age	0.03	.61	0.04	.47

Atrial fibrillation	-0.06	.31	0.01	.86
Head injury	-0.08	.15	-0.15	< .01
Convulsion	0.05	.32	0.19	< .01
Hypertension	0.02	.79	0.02	.74
Current smoking habit	0.02	.80	0.11	.13
Diabetes mellitus	-0.01	.83	-0.004	.94
Body mass index	0.06	.28	0.30	< .01

171

172

173 Discussion

174 The present study provides reference values for the CSA of the VN in Japanese community-

175 dwelling individuals aged 65 years and older. Moreover, multivariable linear regression analysis

176 revealed that the CSA of the VN on the left side was positively associated with a history of

177 convulsion and higher BMI and inversely associated with a history of head injury. In contrast,

178 there were no independent associations between any of the assessed variables and the CSA of

179 the VN on the right side.

180

181 The present study measured the CSA of the VN by ultrasound in a relatively large cohort,
182 compared with previous studies. CSA values for the VN measured by ultrasound in healthy
183 individuals vary widely among different studies, ranging from 1.3 to 6.0 mm² on the right side
184 and from 1.1 to 5.9 mm² on the left side [2–5, 7–12, 15, 20, 22–25] (see Table 4). Since the
185 methodology (ultrasound and resolution) for all these studies were the same, this discrepancy
186 between studies may be explained by differences in the study cohorts. Most previous studies
187 have been conducted in non-Asian countries; however, the CSA values obtained in our study
188 appeared comparable to those found in a small number of Chinese studies [12–14]. For
189 example, the median CSA of the left VN in a pilot study conducted by Du et al. [14] was 1.0
190 mm² (range 1.0–2.0). Moreover, the participants in our study were older than previously studied
191 cohorts, as only participants aged 65 years or older were included. Pelz et al. reported that the
192 CSA of the VN was inversely correlated with age [20], although another study, conducted by
193 Laucius et al., failed to find any differences in VN CSA between younger and older age cohorts
194 [26]; however, the maximum age of the subjects in the latter study was 55 years. Thus, the
195 relatively small CSA of the VN observed in the present study may have been related to the
196 advanced age of the participants. In addition, the somewhat unexpected lack of association
197 between VN CSA and age in our study may have been because in individuals who are already
198 relatively old (≥ 65 years) , the CSA of the VN may be unaffected by further aging.

199

200 **Table 4. Results of current and previous ultrasound studies describing the cross-sectional**
 201 **area of the vagus nerve in healthy individuals**

First author's name	Number of subjects	Age (years), mean (SD)	Height (cm), mean (SD)	Weight (kg), mean (SD)	BMI (kg/m ²), mean (SD)	Right CSA (mm ²), mean (SD)	Left CSA (mm ²), mean (SD)
Present study	336	76.9 (5.5)	155.0 (9.2)	58.3 (11.9)	24.1 (3.8)	1.4 (0.4)	1.2 (0.4)
Sijben LCJ [7] ^a	51	72 (8)	NA	NA	NA	2.2 (0.7)	1.9 (0.6)
Papadopoulou M [9] ^a	28	57 (8.9)	NA	NA	27.3 (4.6)	2.9 (0.8)	2.3 (0.8)
Papadopoulou M [15] ^a	28	50 (NA)	NA	NA	25.4 (NA)	3.2 (0.8)	2.7 (1.1)
Liu L [13] ^b	40	50.8 (12.8)	167.6 (7.8)	65.4 (10.6)	NA	1.3 (0.5)	NA
Horsager J [5] ^a	56	69.1 (8.9)	NA	NA	24.9 (3.7)	2.4 (0.6)	2.0 (0.5)
Sartucci F [25] ^a	20	65.2 (10.3)	169.9 (7.1)	71.0 (16.9)	24.5 (5.0)	6.0 (1.3)	5.6 (1.3)
Holzapfel K [10] ^a	19	63.1 (11.1)	NA	NA	NA	2.2 (0.6)	2.0 (0.3)
Curcean AD [22] ^a	21	25 (2)	174.0 (10.0)	72.0 (17.0)	23.6 (4.4)	2.9 (1.3)	2.1 (0.8)
Walter U [23] ^a	70	M 43.7 (20.3) F 45.5 (19.9)	173.6 (7.9)	74.6 (15.7)	NA	M 1.8 (0.6) F 2.0 (0.7)	M 1.4 (0.5) F 1.6 (0.7)
Pelz JO [3] ^a	35	67.9 (6.2)	167.7 (9.1)	74.9 (14.4)	NA	2.5 (0.5)	1.8 (0.4)

Pelz JO [20] ^a	60	49.7 (19.7)	170.0 (9.0)	71.0 (13.0)	NA	2.6 (0.6)	1.9 (0.4)
Walter U [4] ^a	61	45.1 (20.7)	173.8 (8.1)	75.1 (16.8)	NA	1.3 (0.5)	1.1 (0.5)
Fedtke N [2] ^a	15	NA	NA	NA	NA	2.7 (0.7)	2.4 (0.7)
Cartwright MS [11] ^c	24	38.6 (NA)	NA	NA	NA	NA	5.9 (NA)
Cartwright MS [24] ^c	60	45.9 (NA)	168.0 (NA)	74.5 (NA)	26.5 (NA)	5.0 (2.0)	NA
Weise D [8] ^a	40	65.7 (11.8)	171.0 (9.0)	75.3 (12.1)	25.8 (3.8)	1.6 (0.5)	1.4 (0.5)
Du K [14] ^b	17	47.6 (12.8)	170 (7.0)	66.5 (6.5)	22.0 (1.1)	2.0 [†] (1.0– 3.0) [#]	1.0 [†] (1.0–2.0) [#]
Niu J [12] ^b	105	42 (16.1)	167.2 (8.3)	65 (10.8)	23.2 (2.8)	1.0 ^{†‡} (1.0– 2.0) [#]	

202 VN, vagus nerve; CSA, cross-sectional area; SD, standard deviation; NA, not available; M,

203 Male; F, Female. Studies were conducted in Europe^a, China^b, and the US^c. [†] median value; [#]

204 range; [‡] a single value for the vagus nerve was given.

205

206 Our findings indicated that the CSA of the VN on the left side was associated with BMI.

207 Although an association between BMI and VN CSA is to be expected, some previous reports

208 have indicated a lack of correlation between weight and VN CSA on either side [20, 22, 23].

209 The lower BMI of our study cohort, compared with previous study cohorts, may also have

210 contributed to the smaller VN CSA in our study. Furthermore, our study found no association

211 between the CSA of the VN and DM, despite a previous study showing that the functional status
212 of the VN was reduced in DM patients [27].

213

214 We showed that the CSA of the VN on the left side was significantly smaller in participants
215 with a history of head injury than in those without such a history. Interestingly, history of non-
216 head injury was not associated with the CSA of the VN. The smaller CSA of the left VN in
217 those with prior head injury may be related to autonomic failure. However, this is necessarily
218 somewhat speculative as the exact nature of the head injuries and resulting brain damage was
219 not ascertained in the study participants; further studies are required to verify this association.

220 Traumatic head injury can be caused by orthostatic hypotension, which is a typical symptom of
221 autonomic failure [28]. Head injury due to orthostatic hypotension is especially frequent in the
222 elderly population [29], and orthostatic hypotension is significantly positively associated with
223 falls in older adults [30].

224

225 Heart rate variability can be used to assess autonomic nervous system function and is reportedly
226 inversely associated with the CSA of the left VN [31]. Furthermore, atrophy of the VN has been
227 reported in patients with Parkinson's disease [32] and has been observed to correlate with
228 parasympathetic dysfunction [6]. However, other studies have contradicted these findings [2, 7].

229 Although none of the present study participants had neurological disorders featuring autonomic
230 neuropathy, we are currently conducting a study in patients with Parkinson's disease to
231 investigate the usefulness of CSA of the VN with regard to diagnosis.

232

233 In our cohort, a small percentage of participants had suffered at least one convulsive seizure. As
234 these were older individuals, some of these patients may have been epileptic without having
235 been formally diagnosed. Interestingly, although the relationship between convulsions and CSA
236 of the VN is currently unknown, we showed that the CSA of the VN on the left side was
237 significantly larger in individuals with a history of convulsive seizure. VN stimulation is known
238 to be an effective treatment for epilepsy, reducing the frequency and intensity of seizures [33].

239 The suggested mechanisms include afferent vagal projections to seizure-generating regions in
240 the basal forebrain and insular cortex [34], effects on the locus ceruleus [35,36],

241 desynchronization of hypersynchronized cortical activity [37, 38], and cortical inhibition

242 secondary to the release of inhibitory neurotransmitters [39, 40]. Nonetheless, the precise

243 mechanisms by which VN stimulation therapy achieves seizure reduction have not been fully

244 elucidated. Assuming that the CSA of the VN on the left side might be spontaneously enlarged

245 to control seizures, greater CSA might be a consequence rather than a cause of epilepsy. As this

246 possibility requires further investigation, in future studies we aim to measure the CSA of the

247 VN in patients admitted with convulsive seizures.

248

249 The present study had some limitations. First, the accuracy of the CSA measurements was not

250 examined. Five medical laboratory technicians measured the CSA of the VN in our study

251 cohort, but intra- and inter-observer reliabilities could not be determined as each CSA was

252 measured only once by a single technician. Second, as this was a cross-sectional study, we

253 could not address causal relationships between the variables and the CSA of the VN. Third, the

254 resolution of the ultrasound probes was relatively low for the measurement of nerves; future

255 studies should use probes with resolutions of 15 MHz or more. Fourth, as medical history

256 (including previous injuries) was self-reported by the study participants, there was potential for

257 inaccuracies in the information recorded. Finally, in the future, it will be important to evaluate

258 the CSAs of nerves other than the VN in a Japanese cohort, to see if they are also smaller than

259 the values reported for other populations.

260

261 In conclusion, we determined reference values for the CSA of the VN in a large cohort of

262 community-dwelling elderly Japanese individuals. The CSA of the VN on the left side was

263 positively associated with history of convulsive seizure and BMI and inversely associated with

264 history of head injury. In contrast, there were no independent associations between any of the
265 assessed variables and the CSA on the right side. A longitudinal prospective cohort study is
266 warranted to evaluate the causal relationships between the clinical/background factors identified
267 in this study and the CSA of the VN.

268

269 Acknowledgments

270 We thank Kelly Zammit, BVSc, from Edanz (<https://jp.edanz.com/ac>) for editing a draft of this
271 manuscript and Sarah Ivins from Edanz (<https://jp.edanz.com/ac>) for editing and medical
272 writing support.

273

274


275 References

- 276 1. Knappertz VA, Tegeler CH, Hardin SJ, McKinney WM. Vagus nerve imaging with
277 ultrasound: anatomic and in vivo validation. *Otolaryngol Head Neck Surg.* 1998;118(1):82-85.
- 278 2. Fedtke N, Witte OW, Prell T. Ultrasonography of the Vagus Nerve in Parkinson's
279 Disease. *Front Neurol.* 2018;9:525.
- 280 3. Pelz JO, Belau E, Fricke C, Classen J, Weise D. Axonal Degeneration of the Vagus
281 Nerve in Parkinson's Disease-A High-Resolution Ultrasound Study. *Front Neurol.* 2018;9:951.
- 282 4. Walter U, Tsiberidou P, Kersten M, Storch A, Löhle M. Atrophy of the Vagus Nerve in
283 Parkinson's Disease Revealed by High-Resolution Ultrasonography. *Front Neurol.* 2018;9:805.
- 284 5. Horsager J, Walter U, Fedorova TD, Andersen KB, Skjærbæk C, Knudsen K, et al.
285 Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease-An Ultrasound Case-
286 Control Study. *Front Neurol.* 2021;12:681413.
- 287 6. Huckemann S, Müller K, Averdunk P, Kühn E, Hilker L, Kools S, et al. Cross-
288 sectional area of the vagus nerve correlates with parasympathetic dysfunction in Parkinson's

- 289 Disease. *Clin Neurophysiol.* 2021;132(8): e31-e32.
- 290 7. Sijben LCJ, Mess WH, Walter U, Janssen AML, Kuijf ML, Oosterloo M, et al. The
291 cross-sectional area of the vagus nerve is not reduced in Parkinson's disease patients.
292 *eNeurologicalSci.* 2022;27:100400.
- 293 8. Weise D, Menze I, Metelmann MCF, Woost TB, Classen J, Otto Pelz J. Multimodal
294 assessment of autonomic dysfunction in amyotrophic lateral sclerosis. *Eur J Neurol.* 2022
295 Mar;29(3):715-723.
- 296 9. Papadopoulou M, Bakola E, Papapostolou A, Stefanou MI, Moschovos C, Salakou S,
297 et al. Autonomic dysfunction in amyotrophic lateral sclerosis: A neurophysiological and
298 neurosonology study. *J Neuroimaging.* 2022;32(4):710-719.
- 299 10. Holzapfel K, Naumann M. Ultrasound Detection of Vagus Nerve Atrophy in Bulbar
300 Amyotrophic Lateral Sclerosis. *J Neuroimaging.* 2020;30(6):762-765.
- 301 11. Cartwright MS, Brown ME, Eulitt P, Walker FO, Lawson VH, Caress JB. Diagnostic
302 nerve ultrasound in Charcot-Marie-Tooth disease type 1B. *Muscle Nerve.* 2009;40(1):98-102.
- 303 12. Niu J, Zhang L, Ding Q, Liu J, Zhang Z, Cui L, et al. Vagus Nerve Ultrasound in Chronic
304 Inflammatory Demyelinating Polyradiculoneuropathy and Charcot-Marie-Tooth Disease Type
305 1A. *J Neuroimaging.* 2020;30(6):910-916.
- 306 13. Liu L, Ye Y, Wang L, Song X, Cao J, Qi Y, et al. Nerve ultrasound evaluation of
307 Guillain-Barré syndrome subtypes in northern China. *Muscle Nerve.* 2021;64(5):560-566.
- 308 14. Du K, Xu K, Chu X, Tang Y, Lv H, Zhang W, et al. Vagus nerve ultrasound in
309 transthyretin familial amyloid polyneuropathy: A pilot study. *J Neuroimaging.* 2022;32(2):285-
310 291.
- 311 15. Papadopoulou M, Papapostolou A, Bakola E, Masdrakis VG, Moschovos C, Chroni E,
312 et al. Neurophysiological and ultrasonographic comparative study of autonomous nervous system
313 in patients suffering from fibromyalgia and generalized anxiety disorder. *Neurol Sci.*
314 2022;43(4):2813-2821.
- 315 16. Oura K, Itabashi R, Yamaguchi Oura M, Kiyokawa T, Hirai E, Maeda T. Cross-
316 sectional area of the vagus nerve on carotid duplex ultrasound and atrial fibrillation in acute
317 stroke: A retrospective analysis. *eNeurologicalSci.* 2021;25:100378.
- 318 17. Abdelnaby R, Elsayed M, Mohamed KA, Dardeer KT, Sonbol YT, ELgenidy A, et al.
319 Sonographic Reference Values of Vagus Nerve: A Systematic Review and Meta-analysis. *J Clin*
320 *Neurophysiol.* 2022;39(1):59-71.
- 321 18. Ninomiya T, Nakaji S, Maeda T, Yamada M, Mimura M, Nakashima K, et al. design
322 and baseline characteristics of a population-based prospective cohort study of dementia in Japan:
323 the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). *Environ Health*
324 *Preventive Med.* 2020;25(1):64.

- 325 19. Taguchi K, Iwaoka K, Yamaguchi T, Nozaki R, Sato Y, Terauchi T, et al. A cross-
326 sectional study of Parkinson's disease and the prodromal phase in community-dwelling older
327 adults in eastern Japan. *Clin Park Relat Disord*. 2022;7:100147.
- 328 20. Pelz JO, Belau E, Henn P, Hammer N, Classen J, Weise D. Sonographic evaluation of
329 the vagus nerves: Protocol, reference values, and side-to-side differences. *Muscle Nerve*.
330 2018;57(5):766-771.
- 331 21. Akram DS, Astrup AV, Atinmo T, Boissin JL, Bray GA, Carroll KK, et al. Obesity:
332 preventing and managing the global epidemic. Report of a WHO consultation. *World Health*
333 *Organization technical report series* 2001;894:ixii, 1-ixii, 253.
- 334 22. Curcean AD, Rusu GM, Ducea SM. Ultrasound appearance of peripheral nerves in the
335 neck: vagus, hypoglossal and greater auricular. *Med Pharm Rep*. 2020;93(1):39-46.
- 336 23. Walter U, Tsiberidou P. Differential age-, gender-, and side-dependency of vagus, spinal
337 accessory, and phrenic nerve calibers detected with precise ultrasonography measures. *Muscle*
338 *Nerve*. 2019;59(4):486-491.
- 339 24. Cartwright MS, Passmore LV, Yoon JS, Brown ME, Caress JB, Walker FO. Cross-
340 sectional area reference values for nerve ultrasonography. *Muscle Nerve*. 2008;37(5):566-571.
- 341 25. Sartucci F, Bocci T, Santin M, Bongioanni P, Orlandi G. High-resolution ultrasound
342 changes of the vagus nerve in idiopathic Parkinson's disease (IPD): a possible additional index of
343 disease. *Neurol Sci*. 2021;42(12):5205-5211.
- 344 26. Laucius O, Gabrinovičienė R, Jucevičiūtė N, Vaitkus A, Balnytė R, Petrikonis K, et al.
345 Effect of aging on vagus somatosensory evoked potentials and ultrasonographic parameters of the
346 vagus nerve. *J Clin Neurosci*. 2021;90:359-362.
- 347 27. Yu Y, Hu L, Xu Y, Wu S, Chen Y, Zou W, et al. Impact of blood glucose control on
348 sympathetic and vagus nerve functional status in patients with type 2 diabetes mellitus. *Acta*
349 *Diabetol*. 2020;57(2):141-150.
- 350 28. Robertson D, Robertson RM. Causes of chronic orthostatic hypotension. *Arch Intern*
351 *Med*. 1994;154(14):1620-1624.
- 352 29. Timler D, Dworzyński MJ, Szarpak Ł, Gaszyńska E, Dudek K, Gałązkowski R. Head
353 Trauma in Elderly Patients: Mechanisms of Injuries and CT Findings. *Adv Clin Exp Med*.
354 2015;24(6):1045-1050.
- 355 30. Mol A, Bui Hoang PTS, Sharmin S, Reijnierse EM, van Wezel RJA, Meskers CGM, et
356 al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis.
357 *J Am Med Dir Assoc*. 2019;20(5):589-597.e585.
- 358 31. Pelz JO, Belau E, Menze I, Woost TB, Classen J, Weise D. Correlation between
359 sonographic morphology and function of the cervical vagus nerves. *Auton Neurosci*.
360 2019;220:102552.

- 361 32. Abdelnaby R, Elsayed M, Mohamed KA, Dardeer KT, Sonbol YT, ELgenidy A, et al.
362 Vagus nerve ultrasonography in Parkinson's disease: A systematic review and meta-analysis.
363 *Auton Neurosci*. 2021;234:102835.
- 364 33. González HFJ, Yengo-Kahn A, Englot DJ. Vagus Nerve Stimulation for the Treatment
365 of Epilepsy. *Neurosurg Clin N Am*. 2019;30(2):219-230.
- 366 34. Cechetto DF, Saper CB. Evidence for a viscerotopic sensory representation in the cortex
367 and thalamus in the rat. *J Comp Neurol*. 1987;262(1):27-45.
- 368 35. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the
369 brain by anticonvulsant stimulation of the vagus nerve. *Epilepsy Res*. 1995;22(1):53-62.
- 370 36. Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the
371 seizure-attenuating effects of vagus nerve stimulation. *Epilepsia* 1998;39(7):709-714.
- 372 37. Chase MH, Sterman MB, Clemente CD. Cortical and subcortical patterns of response
373 to afferent vagal stimulation. *Exp Neurol*. 1966;16(1):36-49.
- 374 38. Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation:
375 neurographic correlates of induced EEG synchronization and desynchronization. *Brain Res*.
376 1967;5(2):236-249.
- 377 39. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Meglio M, Colicchio G, Barba C,
378 Papacci F, Tonali PA. Effects of vagus nerve stimulation on cortical excitability in epileptic
379 patients. *Neurology*. 2004;62(12):2310-2312.
- 380 40. Marrosu F, Serra A, Maleci A, Puligheddu M, Biggio G, Piga M. Correlation between
381 GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial
382 epilepsy. *Epilepsy Res*. 2003;55(1-2):59-70.
- 383
384
385
386
387
388



Figure